Copper transport drug restores memory and clears toxic Alzheimer's proteins

The reaction was mostly hostile to the framing, not automatically to the underlying experiment. People kept hammering the same point: this is a mouse result, and Alzheimer’s is littered with mouse successes that never turned into meaningful human benefit. The article headline and body were called misleading because they say "restores memory" without clearly saying "in mice," while the actual journal title does. That mattered because the field has spent decades chasing amyloid-beta, and many readers now see plaque reduction as a weak surrogate rather than persuasive evidence that a treatment will help patients live better or longer. The deeper argument was about what to infer from any amyloid-linked result at this point. Several commenters said the field has shifted toward treating amyloid as a marker or one piece of a broader disease process, not the clean root cause once promised. Others pushed back that anti-amyloid drugs are not a total failure, noting approved antibodies do show measurable slowing of cognitive decline rather than simple plaque removal with zero clinical effect. But even among people open to that view, the mood was that this press release overclaims badly. The more charitable read was that the interesting part is not "we cleared amyloid again" but "we may have altered a waste-removal pathway," which could matter even if amyloid itself is not the causal lever. Personal comments from families dealing with inherited early onset Alzheimer’s added a sobering note that the disease is heterogeneous, with rare genetic forms like PSEN1, PSEN2, and APP mutations potentially behaving differently from the more common late-onset cases.